SOURCE: CLX Medical, Inc.

April 22, 2008 09:22 ET

CLX Medical, Inc. Announces Selection of Laboratory for Pre-Clinical Trials Validation Study on Zonda's Rapid Point of Care Test for Chlamydia

MURRIETA, CA--(Marketwire - April 22, 2008) - CLX Medical, Inc. (OTCBB: CLXN), which owns 51% of Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests for the medical and non-medical markets, today announced that the company has selected IIT Research Institute (IITRI) ( to serve as the laboratory that will conduct a validation study for Zonda's rapid point of care test for chlamydia.

A major purpose of the validation study is to perfect the testing protocol in preparation for the clinical trials as part of the process to achieve FDA clearance for the product.

IIT Research Institute has provided non-clinical research and development services to the U.S. government and to sponsors in the pharmaceutical, biotechnology, chemical, agrichemical, and personal products industries for more than 40 years. IITRI scientists work closely with its sponsors to plan and implement programs in drug discovery, efficacy evaluation, and non-clinical development. Data from GLP-compliant programs conducted at IITRI are commonly used to support Investigational New Drug applications (INDs), New Drug Applications (NDAs), and other submissions to regulatory agencies around the world.

IITRI operates more than 125,000 square feet of state-of-the-art laboratory and support space in its Chicago facility.

IITRI holds accreditations, licensures and registrations a variety of organizations and agencies including the United States Department of Agriculture (USDA), the United States Drug Enforcement Agency (USDEA), and the United States Centers for Disease Control (CDC).

"We are pleased to have selected the laboratory that will conduct the validation study for the Zonda chlamydia product and to have selected a lab with the experience and expertise of IITRI," commented Vera Leonard, chief executive officer of Zonda and CLX. "The study is expected to provide information that will be useful beyond just the clinical trials, so its importance to the advancement of the Zonda product should not be understated."

In addition to their use in preparation for the clinical trials, results from the validation study may be helpful in other applications, such as in overseas markets where additional clinical data can support the sales of the products currently in the market. CLX may also pursue a strategic alliance relationship with an established company in the U.S. medical diagnostic testing market to provide resources and assistance through the clinical trials and FDA clearance application process, and the validation study may help to secure such a relationship.

To sign up to receive information by email directly from CLX Medical, Inc. when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit

About CLX Medical, Inc.

CLX Medical, Inc. ( holds a 51% equity interest in Zonda, Inc. CLX has also invested, and holds a common stock position, in ActionView International, Inc. (, a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Medical, Inc. are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Medical's control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact Information

  • Contact:
    Gemini Financial Communications, Inc.
    A. Beyer
    Email Contact